The increasing interest in peptides has given rise to a significant grey sector, presenting grave risks to individuals. Such products are often manufactured outside controlled regulatory oversight, implying their purity and potency can be highly inconsistent. Furthermore, the vendors may fail to provide truthful data regarding components, possible